Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity

Bibliographic Details
Main Authors:	Po-Lin Huang, Hung-Tsai Kan, Ching-Hsuan Hsu, Hsin-Ta Hsieh, Wan-Chien Cheng, Ren-Yeong Huang, Jhong-Jhe You
Format:	Article
Language:	English
Published:	BMC 2023-08-01
Series:	Journal of Translational Medicine
Online Access:	https://doi.org/10.1186/s12967-023-04410-1

Similar Items

A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
by: Po-Lin Huang, et al.
Published: (2023-05-01)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
by: Yan Feng, et al.
Published: (2022-01-01)

L137 F582 (199-203) [fotograf udara]

Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
by: Kazumasa Oya, et al.
Published: (2021-08-01)

Step AP203 data exchange study /
by: 187988 Clark, Alan L., et al.

ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
by: Peng Zhang, et al.
Published: (2023-08-01)

Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
by: Zuhua Chen, et al.
Published: (2017-12-01)

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

1358 Tissue-targeted lipid nanoparticle delivery for mRNA encoding bispecific T-cell engager demonstrated potent antitumor effects on both hematological malignancies and solid tumors
by: Qi Jiang, et al.
Published: (2023-11-01)

Lipid Nanoparticle Delivery System for mRNA Encoding B7H3‐redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors
by: Cheng Huang, et al.
Published: (2023-01-01)

IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects
by: Yilin Liu, et al.
Published: (2024-01-01)

Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells
by: Yu-Hsuan Kuo, et al.
Published: (2022-04-01)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
by: Ning Shi, et al.
Published: (2022-11-01)

A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
by: Urara Tomita, et al.
Published: (2024-03-01)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
by: Xi Chen, et al.
Published: (2023-06-01)

BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma
by: Ying Liu, et al.
Published: (2023-12-01)

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
by: Lian-sheng Cheng, et al.
Published: (2022-09-01)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
by: Jiahao Qiu, et al.
Published: (2022-04-01)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
by: Daisuke Kamakura, et al.
Published: (2021-11-01)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
by: Alessandro Satta, et al.
Published: (2019-10-01)

Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy
by: Hong Zhang, et al.
Published: (2024-01-01)

Dataset on Cs-137 in waters surrounding Taiwan
by: Ting-Hsuan Huang, et al.
Published: (2023-12-01)

Furan-Conjugated Tripeptides as Potent Antitumor Drugs
by: Hunain Ali, et al.
Published: (2020-12-01)

The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities
by: Lan Deng, et al.
Published: (2023-06-01)

Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models
by: Naiara Martinez-Velez, et al.
Published: (2019-04-01)

Eribulin mesylate exerts antitumor effects via CD103
by: Kazumasa Oya, et al.
Published: (2023-12-01)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
by: Guangtao Zhang, et al.
Published: (2023-05-01)

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
by: Eunhee Lee, et al.
Published: (2023-10-01)

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
by: Antonio Tapia-Galisteo, et al.
Published: (2024-12-01)

Discovery of Novel Quinazoline Derivatives as Potent Antitumor Agents
by: Zhenxi Niu, et al.
Published: (2022-06-01)

Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy
by: Xuefei Bai, et al.
Published: (2021-09-01)

Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells
by: Igor Tsaur, et al.
Published: (2022-06-01)

Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver
by: Hiroyuki Nakashima, et al.
Published: (2023-01-01)

Activated platelet membrane nanovesicles recruit neutrophils to exert the antitumor efficiency
by: Yinghui Shang, et al.
Published: (2022-08-01)

Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer
by: Che-Yuan Hu, et al.
Published: (2023-09-01)

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
by: Caili Xu, et al.
Published: (2023-11-01)

A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer
by: Ting Deng, et al.
Published: (2023-03-01)

1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
by: Benjamin Doranz, et al.
Published: (2023-11-01)

1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism
by: Chao Wang, et al.
Published: (2023-11-01)

CKAP2L Knockdown Exerts Antitumor Effects by Increasing miR-4496 in Glioblastoma Cell Lines
by: Yao-Feng Li, et al.
Published: (2020-12-01)